The largest database of trusted experimental protocols

Phoenix version 8

Manufactured by Certara
Sourced in United States

Phoenix Version 8.3 is a software product developed by Certara. It is a comprehensive data analysis and modeling tool used in the pharmaceutical industry. The software provides advanced capabilities for pharmacokinetic and pharmacodynamic data analysis, modeling, and simulation.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using phoenix version 8

1

Trastuzumab Pharmacokinetic Modeling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Trastuzumab data were simulated using WinNonlin and NLME with Phoenix Version 8.3 (Certara USA, Inc.). We used a published two-compartment population pharmacokinetic model with parallel linear and nonlinear elimination that included the following covariates: body weight (in kg), AST, and albumin24 (link). An R Software package (Version 4.0, http://www.r-project.org/) was used for data assembly, exploratory data analysis, model diagnosis, and simulation.
+ Open protocol
+ Expand
2

Pharmacokinetic Analysis of Trastuzumab

Check if the same lab product or an alternative is used in the 5 most similar protocols
The mean, median, standard deviation, 95% confidence interval, and percentiles of simulated trastuzumab plasma concentrations were calculated using Phoenix Version 8.3 (Certara USA, Inc.) and R Software package (Version 4.0, http://www.r-project.org/).
+ Open protocol
+ Expand
3

In Silico Modeling of Bacterial Kill

Check if the same lab product or an alternative is used in the 5 most similar protocols
PK/PD parameters, which enable a description of the whole-time course of bacterial kill and growth, can be determined in an in silico model (Nielsen and Friberg, 2013 (link)). Dose fractions of 0, 2.5, 5, 10, 15, 20, and 25 mg/kg for single administration and twice-daily administration were inputted in the PBPK/PD model. Concentration–time curves of ADP and bacterial count–time curves can be simulated. PK/PD parameters (AUC/MIC and %T > MIC) are directly calculated by the PBPK model (Mi et al., 2023 (link)). The cumulative area under the curve of the total bacterial count over 24 h (AUC0-24h (Bacterial count)) was used as a bacteriological effect (Pelligand et al., 2019 (link); Ronaghinia et al., 2021 (link)). PK/PD parameters (AUC/MIC and %T > MIC) versus the bacteriological effect, AUC0-24h (Bacterial count), were fitted with an inhibitory sigmoid model (Eq. 4). Curve fitting was performed in Phoenix (version 8.3, Certara, United States), and the best PK/PD parameter related to bacteriological effect was selected. E=E0ImaxINDEXNINDEXN+INDEX50N,
where E0 was the effect under a drug concentration of zero. The maximum possible observed effect is Imax. INDEX was the value of the PK/PD parameters (AUC24h/MIC or %T > MIC). INDEX50 was the value of AUC24h/MIC or %T > MIC, producing a 50% reduction in Imax, and N was the Hill coefficient that described the steepness of the curve.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!